DYRK1B and metabolic syndrome: At least one of these, R102C in metabolic syndrome, is defined as a gain-of-function mutation [26] but clearly exhibits reduced kinase activity, raising the possibility that some effects of DYRK1B may not be strictly dependent on kinase activity.